oncbrain — oncology meeting digest

FIRESTORM

Tue, 09 Jun 2026 00:00:00 GMT

[Caveats dominate] 5-yr PFS 65.8% vs 38.8%, HR 0.40 favoring dose-escalated RT in high-risk meningioma; retrospective IPD meta-analysis. Eligible: High-risk meningioma (WHO grade 2 or recurrent), post-resection (mostly subtotal

NRG Oncology RTOG 0539

Tue, 09 Jun 2026 00:00:00 GMT

[Early signal] 10-yr PFS 85.2%, 72.2%, 42.5% for low/intermediate/high-risk meningioma with risk-adapted observation or RT (median f/u ~12yr). Eligible: WHO grade 1-3 meningioma, post-resection (GTR or STR), newly-diagnosed or recurr

RAPCHEM (BOOG 2010-03)

Tue, 09 Jun 2026 00:00:00 GMT

[Early signal] 10-yr locoregional recurrence 2.9% overall with risk-stratified RT de-escalation after NAC + surgery in cN1 breast cancer. Eligible: Breast cancer cT<5cm cN1-3, receiving NAC prior to BCS or mastectomy

PrTK03 (aglatimagene besadenovec + EBRT)

Thu, 04 Jun 2026 00:00:00 GMT

[Practice-changing] DFS HR 0.70 (0.52–0.94), p=0.016 favoring aglatimagene + valacyclovir + EBRT vs placebo in intermediate/high-risk localized prostate cancer. Eligible: Intermediate/high-risk localized prostate cancer, ECOG 0–2, planning definitive

AREST

Thu, 04 Jun 2026 00:00:00 GMT

[Practice-changing] 3-yr LRFS 89.2% vs 80.9%, HR 0.52 (p=0.02) favoring adj RT in pT1-2 pN0 OSCC with intermediate-risk features; DFS/OS NS. Eligible: pT1-2 pN0 OSCC, intermediate-risk (DOI/PNI/LVE/poor diff), post-curative surgery

mRCAT-III

Tue, 02 Jun 2026 00:00:00 GMT

[Early signal] pCR 61% vs 29% (p<0.0001) with node-sparing SCRT + CAPOX + tislelizumab vs conventional SCRT + CAPOX in pMMR LARC. Eligible: pMMR/MSS LARC, cT3-4N0/+M0, tumor ≤10cm from anal verge, no positive lateral LN

Breast RT + Systemic Therapy Concurrency Review (Speers)

Tue, 02 Jun 2026 00:00:00 GMT

[Confirmatory] T-DXd ILD 9.6% vs T-DM1 1.6% (DESTINY-Breast05); ASCO26 PK-guided concurrency framework for breast RT + systemic agents.

ctDNA surveillance in non-operative rectal cancer management

Mon, 01 Jun 2026 00:00:00 GMT

[Early signal] ctDNA sensitivity only 41% for local regrowth vs 74% for distant mets in 110 NOM rectal pts; risk stratifies but cannot replace imaging. Eligible: Stage I-III MSS rectal, cCR/nCR after NAT, undergoing NOM

PROTEUS

Sun, 31 May 2026 00:00:00 GMT

[Caveats dominate] 53.0% (APA) and 60.7% (ADT) of MFS events PSMA PET-detected; APA+ADT vs ADT benefit in BCR prostate hotly contested. Eligible: Biochemically recurrent prostate cancer, post-radical prostatectomy

COMPPARE

Sun, 31 May 2026 00:00:00 GMT

[Caveats dominate] No sig difference (bowel urgency 5.7% vs 6%, p=0.28; 3-yr BCF 98.0% vs 97.9%) between proton and IMRT in de novo localized prostate. Eligible: De novo localized prostate cancer, excluding very high risk and metastatic

CAN-2409

Sun, 31 May 2026 00:00:00 GMT

[Early signal] DFS HR 0.70 vs placebo (p=0.0155), driven by 2yr biopsy pCR 80.4% vs 63.6%; OS/PCSM immature at 50.3mo. Eligible: High/intermediate-risk localized prostate cancer, RT 78Gy

ENZARAD

Sun, 31 May 2026 00:00:00 GMT

[Confirmatory] MFS HR 0.88 (p=0.34), OS HR 0.87 (p=0.40); enzalutamide added to RT+2y ADT did not improve outcomes in high-risk localized PCa. Eligible: High-risk localized PCa (Gleason 8-10, T3-4, or N1, or PSA ≥20 ng/mL), suitable

MIRACLE-2

Sun, 31 May 2026 00:00:00 GMT

[Early signal] 68% ORR, median OS 23.2mo, 18% NED in MSS unresectable metastatic rectal ca (N=50). Eligible: MSS unresectable metastatic rectal cancer, synchronous mets, first-line

RAD-IO

Sat, 30 May 2026 00:00:00 GMT

[Early signal] 12-month DFS 80% (40/50; 95% CI 0.67-0.89) with durvalumab + chemoRT in MIBC, clearing GO threshold ≥75%; single-arm. Eligible: MIBC cT2-T3, 13% node-positive, 75% prior neoadjuvant chemo, median age 69

MIBC Management Post-pCR / Bladder-Sparing Session

Sat, 30 May 2026 00:00:00 GMT

[Early signal] Durvalumab + CRT (55 Gy/20 fr) feasible in 54 MIBC (87% full RT); pCR after NAC carries 85% 5-yr OS per SWOG 8710. Eligible: MIBC (cT2-4a N0), curative-intent bladder-sparing candidates

NRG Clinico-Transcriptomic Risk Stratification (Abstract 5000)

Sat, 30 May 2026 00:00:00 GMT

[Early signal] 22-gene GC independently predicts MFS, DM, and OS; combined NRG score reclassifies ~25% discordant NCCN high-risk pts for AAP intensification. Eligible: NCCN ≥ high-risk localized prostate cancer, RT+ADT candidates

Neo-CRAG

Sat, 30 May 2026 00:00:00 GMT

[Confirmatory] Adding neoadj CRT to peri-op XELOX: mDFS 52.7 vs 24.4 mo, mOS 67.5 vs 37.6 mo in high-risk LAGC. Eligible: Locally advanced gastric/GEJ adenocarcinoma (cT3N2+, T4), peri-op XELOX eligible

ROADS

Sat, 30 May 2026 00:00:00 GMT

[Practice-changing] Surg bed recurrence 1% (GT) vs 12% (SRS); 2yr OS 62% vs 36% favoring GammaTile in resected brain mets >2cm. Eligible: Resected brain mets >2cm

SENOMAC

Wed, 27 May 2026 00:00:00 GMT

[Confirmatory] 5yr RFS 89.7% vs 88.7%, HR 0.89: SNB alone noninferior to ALND in cN0 breast cancer with 1-2 SN macrometastases. Eligible: cN0 breast cancer, T1-T3, 1-2 SN macrometastases, BCT or mastectomy

SWOG/NRG S1914

Tue, 26 May 2026 00:00:00 GMT

[Confirmatory] No OS benefit from adding atezolizumab to SBRT (HR 1.15, p=0.63); closed for futility; G≥3 AEs 12% vs 2%. Eligible: Inoperable early-stage NSCLC T1-3N0M0 ≤7cm, ≥1 recurrence risk factor

PEACE V–STORM

Fri, 22 May 2026 00:00:00 GMT

[Early signal] 4-yr MFS 76% (ENRT) vs 63% (MDT), HR 0.62 favoring elective nodal RT for PET+ pelvic nodal prostate oligorecurrence. Eligible: Pelvic nodal oligorecurrence (≤5 PET+ nodes), prostate, post-radical tx, PS 0-1

DBCG IMN2

Fri, 22 May 2026 00:00:00 GMT

[Confirmatory] 15-yr OS 65.0% vs 60.8%, HR 0.85 (0.76-0.94), p=0.0016 favoring IMNI in node-positive breast cancer with modern systemic therapy, N=4541. Eligible: Node-positive breast cancer, adjuvant RT, taxane/trastuzumab/AI systemic therapy

Bladder Adjuvant Radiotherapy

Thu, 21 May 2026 00:00:00 GMT

[Early signal] 2-yr LRFS 87.1% vs 76.0% (HR 0.43, p=0.04) favoring adj pelvic IMRT post-cystectomy in high-risk MIBC; DFS/OS NS. Eligible: High-risk urothelial MIBC post-RC (pT3-4, pN+, margin+, or ≤10 nodes), periopera

EORTC 22922/10925

Thu, 21 May 2026 00:00:00 GMT

[Challenges SOC] 20yr OS HR 1.00 (null): BC mortality reduced HR 0.82 but non-BC deaths increased HR 1.26, offsetting benefit. Eligible: Stage I-III breast, node-positive or central/medial tumor, median age 54, post-s

SWOG S1007 RNI analysis

Thu, 21 May 2026 00:00:00 GMT

[Caveats dominate] 5-yr LRR <1% with or without RNI in HR+/HER2-, Oncotype ≤25, N1 breast; IDFS not associated with RNI receipt. Eligible: HR+/HER2-, Oncotype DX ≤25, N1 (1-3 nodes) breast cancer, adjuvant

LS-SCLC 54 Gy Hyperfractionated RT

Wed, 20 May 2026 00:00:00 GMT

[Challenges SOC] mOS 60.7 vs 39.5mo (HR 0.55, p=0.003) favoring 54 Gy hyperfractionated RT in LS-SCLC; no added toxicity. Eligible: LS-SCLC, ECOG 0–1, age 18–70, chemo-naive or ≤1 prior platinum-etoposide cycle

Proton vs Photon PMRT Capsular Contracture (Zerey et al.)

Wed, 20 May 2026 00:00:00 GMT

[Caveats dominate] MVA HR 1.76 (P=0.083) proton vs photon CC, non-significant; proton+DTI 2yr CC 50% vs photon+DTI 35%. Eligible: Post-mastectomy breast cancer, subpectoral TE/I or DTI reconstruction, PMRT cand

Bladder-preserving TMT for MIBC: prognostic factors (ESTRO 2026)

Tue, 19 May 2026 00:00:00 GMT

[Confirmatory] CLR 63.7% in 369 MIBC pts on TMT; 5-FU-based CRT (OR 4.9) and portal imaging frequency independently predicted CLR. Eligible: cT2-T4aNOMO MIBC, median age 76, selected for organ-preserving TMT

ePLND vs PSMA PET staging in prostate cancer (AUA 2026)

Tue, 19 May 2026 00:00:00 GMT

[Challenges SOC] 47.7% of LN mets outside ePLND template; PSMA PET NPV ~96%; RCTs no consistent BCR benefit from routine dissection. Eligible: Localized prostate cancer, intermediate to high risk, primary staging pre-RP

Single-fraction SABR for primary NSCLC and pulmonary oligometastases (pooled analysis, n=1687)

Tue, 19 May 2026 00:00:00 GMT

[Early signal] 2yr LC 90-93%, G3+ AEs 2.9% across 1687 pts treated with SF-SABR at 3 institutions. Eligible: Inoperable primary NSCLC or pulmonary oligomets, multi-institution pooled cohort

PEACE 2

Mon, 18 May 2026 00:00:00 GMT

[Challenges SOC] Pelvic RT did not improve cPFS vs prostate-only RT in VHR localized prostate cancer (HR 0.81, p=0.088). Eligible: VHR localized prostate (≥2: Gleason ≥8, T3-T4, PSA ≥20), N0M0 on conventional im

HEAT Trial

Mon, 18 May 2026 00:00:00 GMT

[Early signal] SBRT 5 fx non-inferior to EHRT for BF (7% vs 7.4%, p-noninferiority=0.007 at 4.25y) in low-int risk PCa; interim data. Eligible: Low-intermediate risk localized PCa, IPSS <12, ADT-eligible

TORPEdO (CRUK/18/010)

Mon, 18 May 2026 00:00:00 GMT

[Challenges SOC] IMPT showed no HR-QoL benefit vs IMRT at 12 months in OPSCC; UW-QoL scores similar across arms to 24 months. Eligible: Oropharyngeal SCC requiring definitive concurrent CRT with bilateral neck treatm

INRT-AIR & DARTBOARD (ENI omission, HNSCC)

Mon, 18 May 2026 00:00:00 GMT

[Early signal] 5-yr solitary ENI recurrence 0% in 117 HNSCC pts on AI-assisted INRT omitting elective nodal fields. Eligible: HNSCC oropharynx/larynx/hypopharynx, stage I-IVB, definitive CRT candidates

OPERA Trial (5-year, rectal preservation)

Mon, 18 May 2026 00:00:00 GMT

[Caveats dominate] 76% good response at W14 by clinical exam; 5yr OP 81% cCR vs 77% nCR; W14 assessment safely identifies W&W candidates. Eligible: Locally advanced rectal cancer, post-neoadjuvant therapy

HCC EBRT Multinational IPD Cohort

Mon, 18 May 2026 00:00:00 GMT

[Confirmatory] BCLC-A mOS 4.6yr, BCLC-0 6.8yr in 4,913-pt IPD cohort; OS comparable to resection and ablation. Eligible: HCC BCLC-0 or BCLC-A, treatment-naïve or previously treated

EXTEND Trial

Mon, 18 May 2026 00:00:00 GMT

[Confirmatory] PFS HR 0.54 (95% CI 0.41-0.72, p<0.001) favoring MDT+SOC across histologies in phase II oligometastatic basket RCT; basket-specific signals identified. Eligible: Oligometastatic solid tumors, 1-5 mets, 6 histology baskets

FASTRACK II (TROG 15.03)

Mon, 18 May 2026 00:00:00 GMT

[Early signal] 100% LC at 84 months in primary RCC (N=70) treated with SABR; G3 AE 10%, no grade 4 events or cancer deaths. Eligible: Inoperable/surgery-declining primary RCC, T1b-dominant, median age 77

NRG/RTOG 1005

Mon, 18 May 2026 00:00:00 GMT

[Practice-changing] 7-yr IBR 2.6% vs 2.2%, HR 1.31 (90% CI 0.84-2.04); concurrent boost noninferior, reducing treatment to 15 fractions. Eligible: Post-lumpectomy high-risk early breast: grade 3, ER-neg, LVI, or close margins

APBI-IMRT Florence

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 15-yr IBTR 7.7% vs 4.2% (HR 1.57, p=0.17); no locoregional control, BCSS, or OS difference confirms APBI de-escalation. Eligible: Early BC post-BCS, pT <25mm, FSM ≥5mm, age >40

DBCG HYPO

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 10-yr G2-3 induration HR 0.76 (19.5% vs 24.7%) favoring 40Gy/15fr; OS and locoregional outcomes equivalent at 12.8yr median f/u. Eligible: Node-negative early breast cancer or DCIS, adjuvant whole-breast RT

IMPORT HIGH

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] 48Gy SIB: 10-yr IBTR 3.7% vs 3.5% sequential boost, non-inferior; further escalation to 53Gy not beneficial (5.5%). Eligible: Invasive early BC (pT1-3, pN0-N3a, M0) post-BCS requiring tumour bed boost RT

EORTC IM-MS (22922/10925)

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] 20-yr OS null (HR 1.00, p=0.967); BCM benefit offset by non-BCM excess; pN0: no benefit. Eligible: Stage I-III BC, node-positive or pN0, adjuvant IM-MS RT decision

DBCG RT Natural

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] 9.8% 4-yr LR without PBI vs 1.5% with PBI in pT1N0 low-risk elderly breast conservation; stopped early per pre-specified threshold. Eligible: ≥60y, pT1N0, ER+ ≥10%, HER2-normal, grade 1-2, unifocal post-lumpectomy

HypoG-01

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] LRR 16% of 118 events; failure patterns comparable between 40 Gy/15fx and 50 Gy/25fx; most in-volume per ESTRO guidelines. Eligible: Early-stage breast cancer, adjuvant hypofractionated RT

Dutch BCRG Breast Boost (Modern Systemic Era)

Sun, 17 May 2026 00:00:00 GMT

[Early signal] 10-yr IBTR 1.2% with or without boost in 0-2 risk-factor BCT pts; boost omission appears safe in modern systemic era. Eligible: Early-stage breast cancer, BCT + WBRT, modern systemic therapy era, stratified b

RAPCHEM

Sun, 17 May 2026 00:00:00 GMT

[Early signal] 10yr locoregional recurrence <3% with nodal-response-guided RT de-escalation after neoadjuvant in breast cancer. Eligible: Node-positive breast cancer achieving pathological nodal response after neoadjuv

EXTEND

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Phase II RCT of MDT added to SOC for oligometastatic solid tumors, all histology baskets; no effect size in source tweet. Eligible: Oligometastatic solid tumors, multiple histologies, all disease sites, systemic

PRIME

Sun, 17 May 2026 00:00:00 GMT

[Early signal] SBRT 5fx with pelvic RT: G3+ toxicity <1%, comparable early BFFS to moderate hypo (N~434); mature 4-5yr endpoint pending. Eligible: High-risk, very high-risk, or node-positive non-metastatic prostate cancer

PIVOTALboost

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Late G2+ bowel 6.5-8.7%, bladder 16.5-24.1% at 2yr, no increase with focal boost or pelvic node RT vs prostate-only (N=1465). Eligible: High-risk localised prostate cancer, moderately fractionated 20-fraction RT

PACE-NODES

Sun, 17 May 2026 00:00:00 GMT

[Early signal] PPN-SBRT increases G≥2 GI toxicity (28% vs 21%) vs prostate-only SBRT; symptoms resolved by 12wk; GU toxicity equivalent; efficacy endpoint pending. Eligible: High-risk localised prostate (T3a-T4, Gleason 8-10, or PSA >20), planned ADT 12-

RADIOSA

Sun, 17 May 2026 00:00:00 GMT

[Caveats dominate] Post-hoc: SBRT + 6mo ADT vs SBRT alone in oligorecurrent prostate; median MFS 16.6mo vs NR, HR 0.39, p=0.0012. Eligible: Oligorecurrent prostate cancer, SBRT candidates, median f/u ~4yr

PEACE-2

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Pelvic RT adds no significant cPFS benefit over prostate-only RT in very high-risk PCa with 3yr ADT (HR 0.81, p=0.088) at interim analysis. Eligible: Very high-risk localized prostate Ca (≥2 of Gleason ≥8, T3-T4, PSA ≥20), N0M0

RCC SBRT 5-year LC

Sun, 17 May 2026 00:00:00 GMT

[Early signal] 100% 5-yr local control for RCC treated with SBRT; no additional endpoints in source.

DIREKHT

Sun, 17 May 2026 00:00:00 GMT

[Unclear] Post-op RT de-intensification in HNSCC: contralateral neck sparing and/or primary CTV dose reduction to 56 Gy; no effect size reported in source tweet. Eligible: Post-operative HNSCC, low contralateral nodal risk subgroup